Revista Española de Cardiología (English Edition) Revista Española de Cardiología (English Edition)
Rev Esp Cardiol. 2017;70:878-80 - Vol. 70 Num.10 DOI: 10.1016/j.rec.2017.01.021

Comparison of Bleeding Risk Scores in Patients With Nonvalvular Atrial Fibrillation Starting Direct Oral Anticoagulants

César Caro Martínez a,, José Manuel Andreu Cayuelas b, Pedro José Flores Blanco b, Mariano Valdés b, José Luis Bailén Lorenzo a, Sergio Manzano Fernández b

a Servicio de Cardiología, Hospital Vega Baja, Orihuela, Alicante, Spain
b Servicio de Cardiología, Hospital Clínico Universitario Virgen de La Arrixaca-IMIB, El Palmar, Murcia, Spain

Article

To the Editor,

We have read with interest the study by Riziq-Yousef Abumuaileq et al.1 in which they demonstrate a similar predictive capacity for the HAS-BLED, ORBIT and ATRIA scoring systems for predicting bleeding complications in patients with atrial fibrillation (AF) being treated with vitamin K antagonists. However, the study that initially validated the ORBIT scoring system2 showed it to be superior to the other 2 scoring systems. Based on these seemingly discordant results, and taking into account the increasing use of direct oral anticoagulants (DOACs), with its specific characteristics in our area, we consider the validation and comparison of these scoring systems to be clinically significant in patients in our environment starting treatment with DOACs.

To this end, a retrospective study was conducted in 3 Spanish hospitals. Between January 2013 and December 2014, 973 consecutive patients with nonvalvular AF who started treatment with DOACs were included. Patients with an indication of temporary anticoagulation or different from AF and those with hypertrophic cardiomyopathy, moderate/severe rheumatic mitral stenosis, carriers of mechanical valvular prostheses or those already taking DOACs were excluded. The 3 bleeding risk scores (HAS-BLED, ATRIA and ORBIT) were calculated in 970 patients (99.7%). During the follow-up period (mean, 646 [470-839] days), bleeding complications were collected by reviewing electronic medical records and through telephone calls in 99.8% of the patients. Bleeding complications were classified according to the International Society on Thrombosis and Hemostasis criteria.3, 4

The population characteristics are shown in Table. A total of 505 patients (51.9%) received rivaroxaban; 188 (19.3%) received dabigatran and 280 (28.8%) received apixaban. During the follow-up period, there were 101 clinically significant bleeding episodes (6.11/100 people/y), 47 major bleeding episodes (2.76/100 people/y), 40 significant gastrointestinal bleeding episodes (2.33/100 people/y), 25 major gastrointestinal bleeding episodes (1.46/100 people/y), 5 episodes of intracranial bleeding (0.29/100 people/y) and 102 deaths (5.85/100 people/y), 34 of which were of cardiovascular origin (1.95/100 people/y). The bleeding rate increased in line with the risk scores (Table 1, Table 2, Table 3 and Table 4 of the supplementary material). All the risk scores showed moderate discriminatory ability (Figure) for both major bleeding—HAS-BLED, 0.62 (95% confidence interval [95%CI], 0.59-0.65); ATRIA, 0.61 (95%CI, 0.58-0.64) and ORBIT, 0.59 (95%CI, 0.56-0.62)—and significant bleeding—HAS-BLED, 0.59 (95%CI, 0.56-0.62); ATRIA, 0.58 (95%CI, 0.55-0.61) and ORBIT, 0.57 (95%CI, 0.54-0.60). The discriminatory ability was somewhat higher for gastrointestinal bleeding—major gastrointestinal bleeding: HAS-BLED, 0.74 (95%CI, 0.71-0.76); ATRIA, 0.71 (95%CI, 0.68-0.74) and ORBIT, 0.69 (95%CI, 0.66-0.72); significant gastrointestinal bleeding: HAS-BLED, 0.69 (95%CI, 0.66-0.72); ATRIA, 0.67 (95%CI, 0.64-0.70) and ORBIT, 0.65 (95%CI, 0.62-0.69). Comparison of the ROC curves of the bleeding risk scoring systems showed no significant differences in any type of event in the general population or after stratification by type of DOAC (all P > .05) (Table 5 of the supplementary material).

Baseline Population Characteristics

 

Variables All
(N = 973)
Rivaroxaban
(n = 505)
Dabigatran
(n = 188)
Apixaban
(n = 280)
P P a P b P c
Age, y 76 ± 9 76 ± 9 74 ± 9 77 ± 8 .001 .002 .491 .001
Sex (female) 529 (54.4) 283 (56) 97 (51.6) 149 (53.2) .522 .296 .446 .731
Hypertension 825 (84.8) 442 (87.5) 151 (80.3) 232 (82.9) .036 .016 .072 .485
Diabetes mellitus 291 (29.9) 133 (26.3) 60 (31.9) 98 (35) .032 .145 .011 .489
Previous stroke and/or TIA 197 (20.2) 79 (15.6) 46 (24.5) 72 (25.7) .001 .007 .001 .761
Heart failure 164 (16.9) 79 (15.6) 30 (16) 55 (19.6) .335 .920 .154 .311
Glomerular filtration rate < 60 mL/min/1.73 m2 339 (34.9) 169 (33.5) 53 (28.3) 117 (41.8) .007 .200 .020 .003
Previous VKA 377 (38.8) 179 (35.5) 85 (45.2) 113 (40.5) .053 .019 .167 .312
Previous labile INR d 243 (65.0) 120 (67.4) 49 (59.0) 74 (65.5) .414 .119 .415 .373
CHADS2 (points) 2.3 ± 1.3 2.2 ± 1.8 2.3 ± 1.4 2.5 ± 1.3 .003 .315 < .001 .086
CHA2DS2-VASc (points) 3.9 ± 1.6 3.8 ± 1.5 3.9 ± 1.8 4.2 ± 1.7 .010 .722 .002 .052
HAS-BLED (points) 1.6 ± 0.9 1.6 ± 0.9 1.6 ± 0.9 1.8 ± 0.9 .041 .909 .018 .051
ATRIA (points) 2.9 ± 1.9 2.9 ± 1.8 2.5 ± 1.7 3.1 ± 2.1 .004 .014 .148 .002
ORBIT (points) 1.7 ± 1.5 1.6 ± 1.5 1.4 ± 1.3 2.0 ± 1.7 < .001 .070 .002 < .001

INR, international normalised ratio; TIA, transient ischaemic attack; VKA, vitamin K antagonists.
Values are expressed as mean ± standard deviation and No. (%).

a Comparison between rivaroxaban and dabigatran.
b Comparison between rivaroxaban and apixaban.
c Comparison between dabigatran and apixaban.
d Data refer to patients with previous use of VKA and known INR control (n = 374).

Risk scoring system discrimination according to events.

Figure. Risk scoring system discrimination according to events.

The results of this study demonstrate that the 3 scoring systems assessed show moderate capacity with no significant differences in discriminating bleeding in patients with nonvalvular AF starting treatment with DOACs. Our results confirm the findings of Riziq-Yousef Abumuaileq et al.1 and also extend their use to patients with AF being treated with DOACs. Given the increasing use of these anticoagulant agents in routine clinical practice, we consider our findings to be clinically significant. Bleeding risk scoring systems are highly useful for identifying patients with a high risk of bleeding who would probably benefit from closer monitoring. Among the different scoring systems available, the HAS-BLED scoring system has become a benchmark in routine clinical practice, as it has various advantages over other published scoring systems. Because this scoring system has been previously validated in various populations with various antithrombotic regimens, it can be applied to a wide population group. Furthermore, the presence of reversible bleeding risk factors that can be modified by clinicians allows patients’ bleeding risk treatment to be considered a nonstatic process, unlike other scoring systems that do not include these potentially modifiable factors. The European Society of Cardiology recently published new clinical practice guidelines for the management of AF.5 Unlike previous guidelines, these do not recommend using a particular bleeding risk scoring system, but rather focus on using any of them to identify and correct potentially modifiable bleeding risk factors.

SUPPLEMENTARY MATERIAL

PDF File

.

Corresponding author: ccaro1980@gmail.com

Bibliography

1. Riziq-Yousef Abumuaileq R, Abu-Assi E, Raposeiras-Roubin S, Rodríguez-Mañero M, Peña-Gil C, González-Juanatey JR. Comparison between 3 bleeding scoring systems in nonvalvular atrial fibrillation patients. What can the new ORBIT score provide?. Rev Esp Cardiol. 2016;69:1112-4.
2. O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36:3258-64.
3. Schulman S, Kearon C. Subcommitte on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-4.
4. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:2119-26.
5. Kirchhof P, Benussi S, Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016.

1885-5857/© 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved

Cookies
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.
Cookies policy
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.